Plain-English translation of NCT06969287 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether , an anti-inflammatory medication, can help prevent delirium—a condition where people become confused, have trouble concentrating, and feel disoriented after surgery. Researchers believe that inflammation in the brain may be a key cause of delirium after surgery. The study will give some patients the medication and others a placebo (a dummy pill) to see if the treatment reduces confusion and other problems that can happen after surgery.
After surgery, some patients experience delirium, which can be scary and lead to longer hospital stays and other complications. Currently, doctors don't have a proven medication to prevent this. This trial is testing whether this medication might help protect people's thinking and memory during recovery.
You likely qualify if…
You likely don't qualify if…
If you enroll, you will receive four doses of either the medication or a placebo—two doses on the day of your surgery and two doses the following day. Researchers will monitor you during your hospital stay using advanced brain monitoring technology and blood tests to track inflammation and brain function. Your participation will help doctors understand whether this treatment can reduce post-surgery confusion.
AI-generated summary from trial data · Aug 9, 2026 · Not medical advice
United States
Phase
Large-scale testing
Sponsor
Washington University School of Medicine
Collaborators
National Institute on Aging (NIA)
Enrollment target
~46 participants
Started
April 2026
Primary completion
April 2027
Age range
60 Years and older
Last updated on clinicaltrials.gov in April 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Sarah Knarr
Washington University School of Medicine
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.